СОВРЕМЕННЫЕ БИОМАРКЕРИ РАННЕГО АТЕРОСКЛЕРОЗА У БОЛЬНЫХ СИСТЕМНОЙ СКЛЕРОДЕРМИЕЙ
Keywords:
tizimli skleroz, ateroskleroz, yurak kasalligi, fibroz, endotelial disfunksiya.Abstract
Tizimli sklerodermiya (TSD) — teri va ichki a'zolar tomonidan geterogen klinik belgilar bilan namoyon boʻladigan tizimli kasallik hisoblanadi. Uning rivojlanishini qoʻzgʻatuvchi mexanizm bu tomirlarning boshlangʻich zararlanishi boʻlib, bunda yalligʻlanish reaktsiyalariga hujayradan tashqari matritsada kollagen va boshqa tarkibiy qismlarini toʻplanishi rivojlanishiga olib keladigan jarayondir. Maqolaning maqsadi sklerodermiyasi boʻlgan bemorlarda yurak va fibrotik biomarkerlarga e'tibor berishdir. Bularga oʻsish omillari, sitokinlar va proteazlar, ularning ingibitorlari, shuningdek, TSD bilan kasallangan bemorlarning teri biopsiyalari va zardobi namunalariga moslashtirilgan hujayradan tashqari matritsa oqsillari, ayniqsa kollagenlar kiradi. Invaziv boʻlmagan fizik va laborator tadqiqotlari boʻyicha umumiy ma'lumotlar taklif qilindi, bu yurak-qon tomir kasalliklari va fibrotik faollikni yaxshiroq tushunishga imkon beradi, potentsial terapevtik javobni baholash uchun samarali ishlatilishi mumkin va TSD uchun samarali davolash usullarini tanlashda yordam beradi.
References
Assassi S., Swindell W.R., Wu M. et al. Dissecting the heterogeneity of skin gene expression patterns in systemic sclerosis // Arthritis Rheum. – 2015. - Vol. 67, №11. – P. 3016-3026. DOI: 10.1002/art.39289.
Ayers N.B., Sun C.M., Chen S.Y. Transforming growth factor-signaling in systemic sclerosis // J. Biomed. Res. – 2018. - Vol. 32, №1. – P. 3-12. DOI: 10.7555/ JBR.31.20170034.
Bosello S., de Santis M., Lama G. et al. B cell depletion in diffuse progressive systemic sclerosis: Safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial // Arthritis Res. Ther. – 2015. - Vol. 12, №2. – P. 54. DOI: 10.1186/ar2965.
Ganiyeva N.A, Rizamukhamedova M.Z., Nabiyeva D.A., Aripova N.A. Clinic - Diagnostic Aspects of Modern Biomarkers of Early Atherosclerosis and Fibrotic activity of Systemic Scleroderma // Asian Journal of Medical Principles and Clinical Practice. – 2021. - Vol. 4, №3. – P. 1-13.
Costa S., Mondini M., Caneparo V. et al. Detection of anti IFI 16 antibodies by ELISA: Clinical and serological associations in systemic sclerosis // Rheumatol. – 2016. - Vol. 50, №4. – P. 674-681. DOI: 10.1093/rheumatology/ keq372.
Farina G., Lafyatis D., Lemaire R. et al. A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis // Arthritis Rheum. – 2010. - Vol. 62. - P. 580-588. DOI: 10.1002/art.27220.
Fett N. Scleroderma: Nomenclature, etiology, pathogenesis, prognosis and treatments: Facts and controversies // Clin. Dermatol. – 2013. - Vol. 31, №4. - P. 432-437. DOI: 10.1016/j. clindermatol.2013.01.010.
Gheita T.A., Hussein H. Cartilage Oligomeric Matrix Protein (COMP) in Systemic Sclerosis (SSc): Role in disease severity and subclinical rheumatoid arthritis overlap // Joint Bone Spine. – 2016. - Vol. 79. - P. 51-56. DOI:10.1016/j. jbspin.2011.02.022.
Pizzorni C., Sulli A., Smith V., Ruaro B., Trombetta A.C., Cutolo M., Paolino S. Primary Raynaud's phenomenon and nailfold videocapillaroscopy: Age-related changes in capillary morphology // Clin Rheumatol. – 2017. - Vol. 36. - P. 1637-1642. 10. Ruaro B., Nallino M.G., Casabella A., Salton F., Confalonieri P., De Tanti A., Bruni C. Monitoring the microcirculation in the diagnosis and follow-up of systemic sclerosis patients: Focus on pulmonary and peripheral vascular manifestations // Microcirculation. – 2020. DOI: 10.1111/micc.12647.
Smith V., Thevissen K., Trombetta A.C., Pizzorni C., Ruaro B., Piette Y., Paolino S., De Keyser F., Sulli A., Melsens K., Cutolo M.N. Capillaroscopy and clinical applications in Systemic Sclerosis // Microcirculation. – 2016. - Vol. 105. P. 119-124.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
